Gerald Faich

Dr. Gerald Faich, MD, MPH, FISPE is the Senior Vice President of UBC's Epidemiology and Risk Management Group and is a recognized leader in drug safety and pharmacoepidemiology. His research interests are risk assessment, pharmacoepidemiology and the design and conduct of registries and streamlined trials for phase IIIb and IV. Before joining UBC, Dr. Faich served in senior management positions at FDA and Corning and provided high-level consulting on safety and risk issues. He is currently a visiting scholar at the University of Pennsylvania and President of the International Society for Pharmacoepidemiology.

Dr. Faich received his undergraduate and medical degrees with honors from the University of Wisconsin. An Internal Medicine residency and Masters degree in Public Health at Harvard followed this. He is a Fellow of the American Colleges of Physicians, Preventive Medicine and Pharmacoepidemiology and has authored over 90 scientific papers and received numerous awards, including FDA's Outstanding Service Award for contributions to Postmarketing Surveillance and Public Health.

From 1983 to 1990, Dr. Faich was the Office Director in charge of statistics and postmarketing surveillance for drugs and biologics at the FDA. There he revitalized the adverse reaction reporting system, revised reporting regulations, expanded staffing and pharmacoepidemiologic research. He co-chaired the original CIOMS International Adverse Reaction Working Group and was a founding board member of the International Society for Pharmacoepidemiology.

After leaving FDA Dr. Faich served as President of PACT, a CRO which focused on postmarketing research and Corning Pharmaceutical Services (now Covance) where he had overall responsibility for toxicology, laboratory testing and phase I to IV clinical trial units. He formed a consulting company in 1996 and joined UBC in 2004.


Gerald Faich Dr. Gerald Faich, MD, MPH, FISPE is the Senior Vice President of UBC's Epidemiology and Risk Management Group and is a recognized leader in drug safety and pharmacoepidemiology. His research interests are risk assessment, pharmacoepidemiology and the design and conduct of registries and streamlined trials for phase IIIb and IV. Before joining UBC, Dr. Faich served in senior management positions at FDA and Corning and provided high-level consulting on safety and risk issues. He is currently a visiting scholar at the University of Pennsylvania and President of the International Society for Pharmacoepidemiology. Dr. Faich received his undergraduate and medical degrees with honors from the University of Wisconsin. An Internal Medicine residency and Masters degree in Public Health at Harvard followed this. He is a Fellow of the American Colleges of Physicians, Preventive Medicine and Pharmacoepidemiology and has authored over 90 scientific papers and received numerous awards, including FDA's Outstanding Service Award for contributions to Postmarketing Surveillance and Public Health. From 1983 to 1990, Dr. Faich was the Office Director in charge of statistics and postmarketing surveillance for drugs and biologics at the FDA. There he revitalized the adverse reaction reporting system, revised reporting regulations, expanded staffing and pharmacoepidemiologic research. He co-chaired the original CIOMS International Adverse Reaction Working Group and was a founding board member of the International Society for Pharmacoepidemiology. After leaving FDA Dr. Faich served as President of PACT, a CRO which focused on postmarketing research and Corning Pharmaceutical Services (now Covance) where he had overall responsibility for toxicology, laboratory testing and phase I to IV clinical trial units. He formed a consulting company in 1996 and joined UBC in 2004.